NCT00947076已完成1 期
A Comparative Bioavailability Study of Fluoxetine Hydrochloride Capsules, 40 mg
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sandoz
- 入组人数
- 30
- 主要终点
- Bioequivalence based on AUC and Cmax
研究概览
简要总结
To demonstrate the relative bioavailability of fluoxetine hydrochloride capsules, 40 mg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
排除标准
- •Positive test results for HIV or hepatitis B or C.
- •Treatment for drug or alcohol dependence.
研究组 & 干预措施
1
Experimental
Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
干预措施: Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc) (Drug)
2
Active Comparator
Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
干预措施: Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly) (Drug)
结局指标
主要结局
Bioequivalence based on AUC and Cmax
时间窗: 42 days
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting ConditionsHealthyNCT00778024Ranbaxy Laboratories Limited36
已完成
1 期
90 mg Fluoxetine Hydrochloride Capsules Under Fasting ConditionsHealthyNCT01247272Teva Pharmaceuticals USA26
已完成
1 期
90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting ConditionsHealthyNCT01247285Teva Pharmaceuticals USA26
已完成
1 期
A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting ConditionsHealthyNCT00992238Padagis LLC48
已完成
1 期
To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting ConditionsPsoriatic ArthritisRheumatoid ArthritisNCT00946686Sandoz52